[1]黄正林.螺内酯治疗射血分数保留性心力衰竭的研究进展[J].心血管病学进展,2022,(9):828-832.[doi:10.16806/j.cnki.issn.1004-3934.2022.09.015]
　HUANG Zhenglin.Role of Spironolactone for Treatment of Heart Failure with Preserved Ejection Fraction[J].Advances in Cardiovascular Diseases,2022,(9):828-832.[doi:10.16806/j.cnki.issn.1004-3934.2022.09.015]
点击复制

螺内酯治疗射血分数保留性心力衰竭的研究进展()
分享到：

《心血管病学进展》[ISSN:51-1187/R/CN:1004-3934]

卷:
期数:
2022年9期
页码:
828-832
栏目:
出版日期:
2022-09-25

文章信息/Info

Title:
Role of Spironolactone for Treatment of Heart Failure with Preserved Ejection Fraction
作者:
黄正林
(雅安市人民医院心内科, 四川 雅安 625000)
Author(s):
HUANG Zhenglin
(Department of Cardiology,The Peoples Hospital of Yaan, Yaan 625000,Sichuan,China)
关键词:
螺内酯; 射血分数保留性心力衰竭; 预后
Keywords:
Spironolactone; Heart failure with preserved ejection fraction; Prognosis
DOI:
10.16806/j.cnki.issn.1004-3934.2022.09.015
摘要:
射血分数保留性心力衰竭（HFpEF）是一类特殊的心力衰竭亚组，其治疗尚无标准模式。作为临床常用的抗心力衰竭药物，螺内酯可改善射血分数降低性心力衰竭患者的心室重塑及预后，但治疗HFpEF是否获益尚无共识。目前研究螺内酯治疗HFpEF常采用随机对照研究方法，内容包括利尿作用及利尿外作用、对生活质量和预后的影响及临床使用影响因素。各研究结论不一致，分析可能与研究对象选择及HFpEF病因复杂相关，也提示螺内酯应用的复杂性。现总结近几年相关研究，以期探索目前螺内酯治疗HFpEF的研究方向和临床应用效果。
Abstract:
The heart failure with preserved ejection fraction(HFpEF) was a special subgroup of heart failure whose treatment has not yet been standardized. As a commonly used anti heart failure drug,spironolactone can improve ventricular remodeling and prognosis in patients with heart failure with reduced ejection fraction,but there is no consensus on whether the treatment of HFpEF benefits. RCT trials were used to study the role of spironolactone for treatment of HFpEF,and the contents include diuretic and extradiuretic effects,the impact on quality of life and prognosis,and the influencing factors of clinical use.?The inconsistent outcomes of many trials might be related to complex baseline of selected subjects and complex etiology of HFpEF,and also indicated the complexity of spironolactone application.?This paper summarizes the relevant research in recent years,in order to explore the current research direction and clinical application effect of spironolactone in the treatment of HFpEF.

参考文献/References:

[1] Kolkhof P, B?rfacker L. 30 YEARS OF THE MINERALOCORTICOID RECEPTOR:mineralocorticoid receptor antagonists:60 years of research and development[J]. J Endocrinol,2017,234(1):T125-T140.

[2] Pieske B,Tsch?pe C,de Boer RA,et al. How to diagnose heart failure with preserved ejection fraction:the HFA-PEFF diagnostic algorithm:a consensus recommendation from the Heart Failure Association(HFA) of the European Society of Cardiology(ESC)[J]. Eur Heart J,2019,40(40):3297-3317.

[3] Andreas BG,Rachna K,Faiez Z,et al. Heart failure with preserved ejection fraction:recent concepts in diagnosis,mechanisms and management[J]. Heart,2022,Jan 12:heartjnl-2021-319605. DOI:10.1136/heartjnl-2021-319605. Epub ahead of print.

[4] 宋雨,李耘,马丽娜. 老年人衰弱和射血分数保留性心力衰竭病理生理学机制的研究进展[J]. 心血管病学进展,2022,43(1):39-40.

[5] Hsu S,Fang JC,Borlaug BA. Hemodynamics for the heart failure clinician:a state-of-the-art review[J]. J Card Fail,2022,28(1):133-148.

[6] Prasad SB,Holland DJ,Atherton JJ. Diastolic stress echocardiography:from basic principles to clinical applications[J]. Heart,2018,104(21):1739-1748.

[7] Jia G,Jia Y,Sowers JR. Role of mineralocorticoid receptor activation in cardiac diastolic dysfunction[J]. Biochim Biophys Acta Mol Basis Dis,2017,1863(8):2012-2018.

[8] Edelmann F,Wachter R,Schmidt AG,et al. Effect of spironolactone on diastolic function and exercise capacity in patients with heart failure with preserved ejection fraction:the Aldo-DHF randomized controlled trial[J]. JAMA,2013,309(8):781-791.

[9] Ferreira JP,Girerd N,Rocca HB,et al. No influence of spironolactone on plasma concentrations of angiotensin-converting enzyme 2:findings from the HOMAGE randomized trial[J]. Arch Cardiovasc Dis,2021,114(12):814-817.

[10] Anand IS,Claggett B,Liu J,et al. Interaction between spironolactone and natriuretic peptides in patients with heart failure and preserved ejection fraction:from the TOPCAT trial[J]. JACC Heart Fail,2017,5(4):241-252.

[11] Chen Y, Wang?H,Lu Y,et al. Effects of mineralocorticoid receptor antagonists in patients with preserved ejection fraction:a meta-analysis of randomized clinical trials[J]. BMC Med,2015,13:10.

[12] Verbrugge?FH,Omote?K,Reddy YNV,et al. Heart failure with preserved ejection fraction in patients with normal natriuretic peptide levels is associated with increased morbidity and mortality[J]. Eur Heart J,2022,43(20):1941-1951.

[13] Ferreira JP,Rossignol P,Claggett BL.?Weight changes in heart failure with preserved ejection fraction:findings from TOPCAT[J]. Clin Res Cardiol,2022,111(4):451-459.

[14] Kurrelmeyer KM,Ashton Y,Xu J,et al. Effects of spironolactone treatment in elderly women with heart failure and preserved left ventricular ejection fraction[J]. J Card Fail,2014,20(8):560-568.

[15] Ferreira JP, Verdonschot AJ, Girerd N,et al. Influence of ejection fraction on biomarker expression and response to spironolactone in people at risk of heart failure:findings from the HOMAGE trial[J]. Eur J Heart Fail,2022, 24(5):771-778.

[16] Cleland JGF, Ferreira JP, Mariottoni B,et al. The effect of spironolactone on cardiovascular function and markers of fibrosis in people at increased risk of developing heart failure:the heart ’OMics’ in AGEing(HOMAGE) randomized clinical trial[J]. Eur Heart J,2021,42(6):684-696.

[17] Tromp J,Westenbrink BD,Ouwerkerk W,et al. Identifying pathophysiological mechanisms in heart failure with reduced versus preserved ejection fraction[J]. J Am Coll Cardiol,2018,72(10):1081-1090.

[18] Schnelle M, Leha A, Eidizadeh A,et al. Plasma biomarker profiling in heart failure patients with preserved ejection fraction before and after spironolactone treatment :results from the Aldo-DHF trial[J]. Cells,2021,10(10):2796.

[19] Dumeny?D,Vardeny O, Edelmann F,et al. NR3C2 genotype is associated with response to spironolactone in diastolic heart failure patients from the Aldo-DHF trial[J]. Pharmacotherapy,2021,41(12):978-987.

[20] Shantsila?E,Shahid?F,Sun Y,et al. Spironolactone in atrial fibrillation with preserved cardiac fraction:the IMPRESS-AF trial[J]. J Am Heart Assoc,2020,9(18):e016239.

[21] Lewis EF,Kim HY,Claggett B,et al. Impact of spironolactone on longitudinal changes in health-related quality of life in the treatment of preserved cardiac function heart failure with an aldosterone antagonist trial[J]. Circ Heart Fail,2016,9(3):e001937.

[22] Upadhya B,Hundley WG,Brubaker PH,et al. Effect of spironolactone on exercise tolerance and arterial function in older adults with heart failure with preserved ejection fraction[J]. J Am Geriatr Soc,2017,65(11):2374-2382.

[23] Kosmala W,Rojek A,Przewlocka-Kosmala M,et al. Effect of aldosterone antagonism on exercise tolerance in heart failure with preserved ejection fraction[J]. J Am Coll Cardiol,2016,68(17):1823-1834.

[24] Li S,Zhang X,Dong M,et al. Effects of spironolactone in heart failure with preserved ejection fraction:a meta-analysis of randomized controlled trials[J]. Medicine,2018,97(35):e11942.

[25] Fukuta H,Goto T,Wakami K,et al. Effects of mineralocorticoid receptor antagonists on left ventricular diastolic function,exercise capacity,and quality of life in heart failure with preserved ejection fraction:a meta-analysis of randomized controlled trials[J]. Heart Vessels,2018,34(4):597-606.

[26] Pitt B, Pfeffer MA, Assmann SF. Spironolactone for heart failure with preserved ejection fraction[J]. N Engl J Med,2014,370(15):1383-1392.

[27] Kalogeropoulos AP, Thankachen J,Butler J,et al. Diuretic and renal effects of spironolactone and heart failure hospitalizations:a TOPCAT Americas analysis[J]. Eur J Heart Fail,2020,22(9):1600-1610.

[28] Ferreira JP,Liu J,Claggett BL,et al. Outpatient diuretic intensification as endpoint in heart failure with preserved ejection fraction trials:an analysis from TOPCAT[J]. Eur J Heart Fail,2022,24(2):378-384.

[29] Flint KM, Shah SJ, Lewis EF,et al. Variation in clinical and patient-reported outcomes among complex heart failure with preserved ejection fraction phenotypes[J]. ESC Heart Fail,2020,7(3):811-824.

[30] Packer M. Derangements in adrenergic-adipokine signalling establish a neurohormonal basis for obesity-related heart failure with a preserved ejection fraction[J]. Eur J Heart Fail,2018,20(5):873-878.

[31] Packer M. Obesity-associated heart failure as a theoretical target for treatment with mineralocorticoid receptor antagonists[J]. JAMA Cardiol,2018,3(9):883-887.

[32] Efstratios K,Ramanjit K,Heinrich T,et al. Obesity and heart failure with preserved ejection fraction[J]. Heart Fail Clin,2021,17(3):345-356.

[33] Shah SJ,Kitzman DW,Borlaug BA,et al. Phenotype-specific treatment of heart failure with preserved ejection fraction:a multiorgan roadmap[J]. Circulation,2016,134(1):73-90.

[34] Pfeffer MA, Claggett B, Assmann SF,et al. Regional variation in patients and outcomes in the Treatment of Preserved Cardiac Function Heart Failure With an Aldosterone Antagonist (TOPCAT) trial[J]. Circulation,2015,131(1):34-42.

[35] Verdonschot JAJ,Ferreira JP,Pizard A,et al. The effect of spironolactone in patients with obesity at risk for heart failure:proteomic insights from the HOMAGE trial[J]. J Card Fail,2022,28(5):778-786.

[36] Potter E,Stephenson G,Harris J,et al. Screening-guided spironolactone treatment of subclinical left ventricular dysfunction for heart failure prevention in at-risk patients[J]. Eur J Heart Fail,2022,24(4):620-630.

[37] Beldhuis IE, Myhre PL, Bristow M,et al. Spironolactone in patients with heart failure,preserved ejection fraction,and worsening renal function[J]. J Am Coll Cardiol,2021,77(9):1211-1221.

[38] Almedeny SA,Al-Mayah JY,Abdulzahra MS,et al. The effect of spironolactone on serum electrolytes and renal function tests in patients with severe chronic heart failure[J]. Wiad Lek,2021,74(10 pt 1):2460-2462.

[39] Desai RJ, Solomon SD, Vaduganathan M. Rates of spironolactone initiation and subsequent hyperkalemia hospitalizations in patients with heart failure with preserved ejection fraction following the TOPCAT trial:a cohort study of Medicare beneficiaries[J]. J Card Fail,2022,28(6):1035-1039.

[40] Epstein M,Calhoun DA. Aldosterone blockers(mineralocorticoid receptor antagonism) and potassium-sparing diuretics[J]. J Clin Hypertens,2011,13(9):644-648.

[41] Bommareddy K, Hamade?H,Lopez-Olivo MA,et al. Association of spironolactone use with risk of cancer:a systematic review and meta-analysis[J]. JAMA Dermatol,2022,158(3):275-282.

[42] Ferreira JP, Rossello?X,Pocock?SJ,et al. Spironolactone dose in heart failure with preserved ejection fraction:findings from TOPCAT[J]. Eur J Heart Fail,2020,22(9):1615-1624.

[43] Sperry BW, Hanna M, Shah SJ. Spironolactone in patients with an echocardiographic HFpEF phenotype suggestive of cardiac amyloidosis:results from TOPCAT[J]. JACC Heart Fail,2021,9(11):795-802.

[44] Safdar Z,Cho E. Effect of spironolactone use in pulmonary arterial hypertension—Analysis from pivotal trial databases[J]. Pulm Circ,2021,11(4):20458940211045618.

[45] Tsujimoto T, Kajio H.?Spironolactone use and improved outcomes in patients with heart failure with preserved ejection fraction with resistant hypertension[J]. J Am Heart Assoc,2020,9(23):e018827.

[46] 徐俊波,黄刚,蔡琳. 2019 ESC-HFA射血分数保留性心力衰竭诊断共识的解读[J]. 心血管病学进展,2019,40(9):1193-1195,1121.

相似文献/References:

[1]孙慧雪 郑美芳 李海 孙磊 顾翔.远程医疗应用于射血分数保留性心力衰竭的现状及进展[J].心血管病学进展,2020,(3):251.[doi:10.16806/j.cnki.issn.1004-3934.20.03.009]
　SUN Huixue,ZHENG Meifang,LI Hai,et al.Status Progress of Telemedicine in Heart Failure with Preserved Ejection Fraction[J].Advances in Cardiovascular Diseases,2020,(9):251.[doi:10.16806/j.cnki.issn.1004-3934.20.03.009]
[2]菲尔凯提·玉山江李昊穆叶赛·尼加提.射血分数保留性心力衰竭合并糖尿病的研究进展[J].心血管病学进展,2020,(4):373.[doi:10.16806/j.cnki.issn.1004-3934.2020.04.011]
　FEIERKAITI·Yushanjiang,LIHao,MUYESAI.Nijiati.Heart Failure With Preserved Ejection Fraction and Diabetes Mellitus[J].Advances in Cardiovascular Diseases,2020,(9):373.[doi:10.16806/j.cnki.issn.1004-3934.2020.04.011]
[3]高可 杨蕾 姚新叶 郑小璞.射血分数保留性心力衰竭动物模型的研究进展[J].心血管病学进展,2020,(8):834.[doi:10.16806/j.cnki.issn.1004-3934.2020.08.013]
　GAO Ke,YANG Lei,YAO Xinye,et al.Advances in Animal Models ofHeart Failure with Preserved Ejection Fraction[J].Advances in Cardiovascular Diseases,2020,(9):834.[doi:10.16806/j.cnki.issn.1004-3934.2020.08.013]
[4]汪羚利 李昭屏.盐皮质激素受体拮抗剂在难治性高血压中的应用现状[J].心血管病学进展,2020,(10):1026.[doi:10.16806/j.cnki.issn.1004-3934.2020.10.007]
　WANG Lingli,LI Zhaoping.Application Status of Mineralocorticoid-receptor Antagonists in Resistant Hypertension[J].Advances in Cardiovascular Diseases,2020,(9):1026.[doi:10.16806/j.cnki.issn.1004-3934.2020.10.007]
[5]刘春秋 熊双 刘剑刚 董国菊.射血分数保留性心力衰竭的诊断的研究进展[J].心血管病学进展,2021,(9):784.[doi:10.16806/j.cnki.issn.1004-3934.2021.09.000]
　LIU Chunqiu,XIONG Shuang,LIU Jiangang,et al.Diagnosis of Heart Failure with Preserved Ejection Fraction[J].Advances in Cardiovascular Diseases,2021,(9):784.[doi:10.16806/j.cnki.issn.1004-3934.2021.09.000]
[6]宋雨 李耘 马丽娜.老年人衰弱和射血分数保留性心力衰竭病理生理学机制的研究进展[J].心血管病学进展,2022,(1):38.[doi:10.16806/j.cnki.issn.1004-3934.2022.01.010]
　SONG Yu,LI Yun,MA Lina.Pathophysiological Mechanisms of Frailty and Heart Failure with Preserved Ejection Fraction in the Elderly[J].Advances in Cardiovascular Diseases,2022,(9):38.[doi:10.16806/j.cnki.issn.1004-3934.2022.01.010]
[7]赵菲 刘永铭.抗炎类药物对射血分数保留性心力衰竭患者心外膜脂肪组织的影响[J].心血管病学进展,2022,(1):41.[doi:10.16806/j.cnki.issn.1004-3934.2022.01.011]
　ZHAO Fei,LIU Yongming.Effects of Anti-Inflammatory Drugs on Epicardial Adipose Tissue in Patients with Heart Failure with Preserved Ejection Fraction[J].Advances in Cardiovascular Diseases,2022,(9):41.[doi:10.16806/j.cnki.issn.1004-3934.2022.01.011]
[8]张文珺 牛小伟 刘永铭.m6A甲基化在射血分数保留性心力衰竭中的作用的研究进展[J].心血管病学进展,2022,(1):44.[doi:10.16806/j.cnki.issn.1004-3934.2022.01.012]
　ZHANG Wenjun,NIU Xiaowei,LIU Yongming.m6A RNA Methylation in Heart Failure with Preserved Ejection Fraction[J].Advances in Cardiovascular Diseases,2022,(9):44.[doi:10.16806/j.cnki.issn.1004-3934.2022.01.012]
[9]聂琼 吴镜.射血分数保留性心力衰竭：从机制到治疗[J].心血管病学进展,2022,(3):258.[doi:【DOI】10.16806/j.cnki.issn.1004-3934.2022.03.0170]
　NIE Qiong,WU Jing.Heart Failure with Preserved Ejection Fraction:from Mechanism to Treatment[J].Advances in Cardiovascular Diseases,2022,(9):258.[doi:【DOI】10.16806/j.cnki.issn.1004-3934.2022.03.0170]
[10]卢甜甜 张轶.射血分数保留性心力衰竭左心室心肌力学变化及评估的研究进展[J].心血管病学进展,2022,(4):331.[doi:10.16806/j.cnki.issn.1004-3934.2022.04.011]
　LU Tiantian,ZHANG Yi?/html>.Changes and Evaluation of Left Ventricular Myocardial Mechanical?n Heart Failure with Preserved Ejection Fraction[J].Advances in Cardiovascular Diseases,2022,(9):331.[doi:10.16806/j.cnki.issn.1004-3934.2022.04.011]

备注/Memo

备注/Memo:
收稿日期： 2022-03-25
更新日期/Last Update: 2022-10-24